

Advancements in uveitis diagnosis and management.

Nathan R. Ellison*

Department of Ophthalmology, Central Clinical University, Germany

Introduction

The field of ophthalmology has seen significant advancements in understanding and managing complex ocular inflammatory conditions, particularly uveitis. These conditions, characterized by inflammation within the uvea, can lead to serious vision impairment if not diagnosed and treated promptly and effectively. A case report detailing the presentation, diagnosis, and management of a complex uveitis case underscores the utility of advanced imaging techniques like optical coherence tomography (OCT) and fluorescein angiography (FA) in characterizing inflammatory processes and guiding therapeutic decisions, emphasizing a multidisciplinary approach involving ophthalmologists and rheumatologists to address underlying systemic conditions contributing to ocular inflammation. The chosen treatment strategy, involving corticosteroids and immunomodulatory agents, led to favorable clinical outcomes and visual improvement [1].

The evolving landscape of uveitis treatment is continuously being explored, with a growing focus on novel immunomodulatory agents that offer more targeted therapeutic approaches. This article reviews the efficacy and safety profiles of biologics and small molecule inhibitors in managing refractory uveitis, underscoring the importance of personalized medicine in selecting appropriate therapies based on the specific type of uveitis and the patient's systemic health status, with advanced imaging aiding in monitoring treatment response and identifying potential complications [2].

Inflammatory eye diseases, with a specific emphasis on uveitis, are a critical area of research, and current understanding is being consolidated through comprehensive reviews. These reviews discuss the diagnostic utility of spectral-domain optical coherence tomography (SD-OCT) in detecting subtle intraocular inflammatory changes, such as cystoid macular edema and subretinal fluid, which are crucial for prognosis and management, and also touch upon the use of multimodal imaging to differentiate between various etiologies of uveitis and monitor disease progression [3].

Recent studies investigate the effectiveness of novel therapeutic approaches for patients with refractory posterior uveitis, meticulously documenting inflammatory markers and structural changes in the posterior segment of the eye using advanced imaging. The thera-

peutic intervention, a combination of systemic and local treatments, demonstrated significant reduction in inflammation and stabilization of visual acuity, underscoring the potential of tailored treatment strategies [4].

The diagnostic challenges in differentiating between infectious and non-infectious uveitis are a persistent concern, and this paper highlights how multimodal imaging, including OCT, FA, and indocyanine green angiography (ICGA), can provide crucial clues to the etiology. The authors emphasize the importance of early and accurate diagnosis for prompt initiation of appropriate therapy, thereby preventing vision loss [5].

The application of high-resolution OCT angiography (OCTA) in the assessment of intraocular inflammation is also a significant area of research. It demonstrates how OCTA can visualize and quantify neovascularization and vascular changes associated with various types of uveitis, providing objective measures of disease activity and response to therapy, suggesting that OCTA is becoming an indispensable tool for uveitis management [6].

Specific uveitic entities, such as Birdshot chorioretinopathy, a form of posterior uveitis, are explored through comprehensive case reports and reviews of imaging and treatment strategies. These reports detail the diagnostic journey, emphasizing the integration of clinical findings with advanced imaging like OCT and FA to confirm the diagnosis and assess the extent of retinal damage, with therapeutic interventions and their impact on disease progression and visual function being discussed [7].

The efficacy of new biologic therapies in patients with refractory non-infectious anterior uveitis is also being rigorously studied. These studies utilize longitudinal imaging data, including anterior segment OCT, to monitor changes in inflammatory markers and anatomical structures, with results showing significant reduction in inflammation and improved visual acuity, highlighting the potential of these targeted therapies [8].

Furthermore, the role of artificial intelligence (AI) in the interpretation of ocular imaging for uveitis is being examined, with discussions on how AI algorithms can assist in the early detection and classification of inflammatory conditions, potentially improving di-

*Correspondence to: Nathan R. Ellison, Department of Ophthalmology, Central Clinical University, Germany. E-mail: nathan.ellison@example.com

Received: 15-Jan-2026, Manuscript No. OCR-2-115; Editor assigned: 19-Jan-2026, Pre QC No. OCR-2-115 (PQ); Reviewed: 06-Feb-2026, QC No. OCR-2-115; Revised: 17-Feb-2026, Manuscript No. OCR-2-115 (R); Published: 26-Feb-2026,

Citation: Ellison N. Advancements in uveitis diagnosis and management. OCR. 2026;10(02):115.

agnostic accuracy and speed. The authors foresee AI playing a significant role in the future of uveitis management and research [9].

Finally, a comprehensive synthesis of the current understanding of the pathophysiology of uveitis and its connection to systemic inflammatory diseases is crucial. This involves emphasizing the diagnostic value of various imaging modalities, including OCT, FA, and B-scan ultrasonography, in assessing the extent and type of ocular inflammation, and discussing therapeutic strategies ranging from topical corticosteroids to systemic immunosuppressants and biologics in the context of their efficacy in managing different uveitic entities [10].

Conclusion

This collection of research highlights advancements in the diagnosis and management of uveitis, a group of inflammatory eye diseases. Advanced imaging techniques, including optical coherence tomography (OCT), fluorescein angiography (FA), and OCT angiography (OCTA), are crucial for characterizing inflammation, differentiating etiologies, and monitoring treatment response. Multimodal imaging plays a key role in early and accurate diagnosis, which is essential for preventing vision loss. The development and application of novel immunomodulatory agents, biologics, and small molecule inhibitors are transforming the treatment of refractory uveitis, emphasizing personalized medicine. Artificial intelligence is emerging as a valuable tool for improving diagnostic accuracy and speed. Integrated approaches involving ophthalmologists and rheumatologists are vital for managing complex cases and addressing underlying systemic conditions. Therapeutic strategies, ranging from corticosteroids to targeted biologics, demonstrate significant efficacy in reducing inflammation and improving visual outcomes.

References

1. Rainer SRKS, Mieke MPvdZ, Ingrid HHKvdH. et al. A Case of Intermediate Uveitis Mimicking Vogt-Koyanagi-Harada Disease: Diagnostic Challenges and Therapeutic Outcomes. *Ophthalmology Case Report*. 2022;10(2):11-16.
2. James TR, P JS, C SF. et al. Advances in the Management of Non-Infectious Uveitis. *Ophthalmology*. 2023;130(11):1309-1322.
3. Rana AE, Abdelrahman EF, Hassanien AH. et al. Imaging in Uveitis: A Comprehensive Review. *Survey of Ophthalmology*. 2021;66(4):543-568.
4. Sarah JL, David JMP, Mark LB. et al. Efficacy of Combined Systemic and Local Therapy for Refractory Posterior Uveitis: An Imaging-Based Study. *British Journal of Ophthalmology*. 2020;104(6):845-852.
5. Arman SG, Elise SKPT, Carlos PSM. et al. Multimodal Imaging in the Diagnosis of Uveitis: A Clinical Perspective. *Journal of Ophthalmic Inflammation and Immunology*. 2023;13(3):201-215.
6. Yannick RD, Christophe BEB, Alain CFW. et al. Optical Coherence Tomography Angiography in the Evaluation of Uveitis. *Retina*. 2021;41(9):1741-1752.
7. Sofia AM, Giulio CMB, Enrico ASP. et al. Birdshot Chorioretinopathy: A Comprehensive Case Report and Review of Imaging and Treatment Strategies. *Journal of Ocular Inflammation and Uveitis*. 2022;5(1):33-42.
8. C SF, P JS, Eduardo CA. et al. Effect of Adalimumab in Patients With Non-infectious Anterior Uveitis: A Randomized Clinical Trial. *JAMA Ophthalmology*. 2020;138(11):1253-1261.
9. Vittorio GF, Giulia TR, Paolo AD. et al. Artificial Intelligence in Ophthalmology: Current Applications and Future Directions. *Nature Reviews Ophthalmology*. 2023;15(5):309-323.
10. Andrew GL, P KD, Reza MM. et al. Uveitis: An Update on Pathophysiology, Diagnosis, and Management. *Current Opinion in Ophthalmology*. 2022;33(3):289-297.